מלגות ופרסים של האגודה האנדוקרינית

המועד הבא להגשת בקשות למלגת נסיעה לכנס בינלאומי לחוקרים צעירים הוא 30 בנובמבר. כאמור השנה
עודכן גובה התמיכה, לאירופה 3,500 ₪ לארה"ב 5,000 ₪. פרטים באתר

חברי האגודה מוזמנים להגיש בקשות לשתי מלגות מחקר במימון האגודה המיועדים לחוקרים צעירים בתחומים קליניים או בסיסים בסך 40,000 ₪ כ"א. לפרטים נוספים לפנות למזכירות האגודה

הר"י: עדכונים למתמחים

מידע למתמחים על מבחני ההתמחות בלינק הבא

European Society of Endocrinology

לצפייה בניוזלטר אחרון של איגוד אנדוקריני אירופאי נא להקליק כאן

British Thyroid Association Guidelines for the Management of Thyroid Cancer

קווי מנחה חדשים לטיפול סרטן תירואיד של איגודים בריטים פורסמו לאחרונה
במוסף של עיתון Clinical Endocrinology. לצפייה לחצו כאן

• ב 15/10/14 – כנס שנתי GH & IGF society (Signapore)
• ב 22/10/14 – 2nd Course on Neuroendocrine Tumors (הדסה)
• ב 23/10/14  – כנס EndoBridge 2014 (Antalya, Turkey)
• ב 26/10/14 – פורום סרטן בלוטת התריס (סורוקה)
• ב 29/10/14 – ATA Annual Meeting (California)
• ב 21/11/14 – ENS@T Scientific Meeting (Nice)
• ב 27/11/14 – כנס חורף של אגודה ישראלית לאנדוקרינולוגיה (אילת)
• ב 05/03/15 – ENDO 2015 Meeting (San Diego)
• ב 11/03/14 – ENETS Annual Conference (Barcelona)
• ב 16/05/15 – European Congress of Endocrinology (Dublin)

Studies Find Popular Diets Are Nearly The Same For Weight Loss.
A study in JAMA reported that using either a low-carb or low-fat diet will have the same result on weight loss. Another study published in Annals of Internal Medicine found that subjects on a low-carb diet had fewer cardiovascular risks than those on a low-fat diet.
להמשך קריאה

FDA Says Little Evidence Testosterone Treatment Works.
FDA says there’s little evidence that testosterone boosting drugs taken by millions of American men are actually effective. The FDA’s comments come ahead of a public meeting to discuss the benefits and risks of treatments that raise levels of testosterone after two federally funded studies found links between testosterone therapy and heart problems in men.
להמשך קריאה

Oral Calcium-Sensing Receptor Antagonist Fails To Boost BMD In Osteoporosis.
According to a phase II study published the JCEM, postmenopausal women with osteoporosis treated with the oral calcium-sensing receptor antagonist MK-5442, showed increases s-P1NP levels compared with the placebo, but no significant increases in BMD were seen at six months at the lumbar spine, total hip, femoral neck, or trochanter.
להמשך קריאה

Prediabetes May Be Linked To An Increased Risk Of Cancer.
A study in Diabetologia looking at data from 16 studies with nearly 900,000 people from around the world report that people with prediabetes had a 15 percent overall increased risk of cancer. Significant associations were found between prediabetes and stomach, colorectal, liver, pancreas, breast and endometrial cancers, but not with lung, prostate, ovarian, kidney or bladder cancers.
להמשך קריאה

Firm Abandons Work On Diabetes Medicine After Manipulation Of Study Data.
Wall Street Journal reports Hyperion Therapeutics disclosed it is discontinuing work on its experimental diabetes treatment DiaPep277 for type 1 diabetes after discovering of employees of Andromeda Biotech, the original producer of the drug, allegedly manipulated study data.
להמשך קריאה

Weekly Injectable Diabetes Medication Receives FDA Approval.
Eli Lilly and Co.’s new weekly injectable diabetes medicine, Trulicity (dulaglutide), received approval from the FDA for Type 2 diabetes treatment in adults. The FDA disclosed that the safety and efficacy had been studied in 3,342 type 2 diabetics.
להמשך קריאה

Lilly, Boehringer long lasting insulin gets EU approval
Eli Lilly and Boehringer Ingelheim received approval from the European Commission to market their long-lasting insulin Abasria, which is subject of patent infringement litigation with French rival Sanofi. Last month the FDA gave a tentative approval to the insulin named Basaglar in the US.
להמשך קריאה

Artificial Sweeteners Tied To Glucose Intolerance, Altered Gut Microbiota.
A study in Nature from the Weizmann Institute of Science in Israel reports that mice fed the artificial sweeteners experienced increased risk of glucose intolerance. Researchers then monitored seven human volunteers who did not use artificial sweeteners but were given regular doses of saccharin over a week. Four volunteers developed glucose intolerance. A computer algorithm looked at gut microbes of the seven people and clustered them into two groups, one affected by artificial sweeteners and the other not.
להמשך קריאה

FDA Advisory Panel Recommends Curbs On Testosterone Medications.
An outside advisory panel voted for the FDA to impose strict new limitations on the multibillion-dollar testosterone drug industry. The panel recommended the agency seek tougher labels for the medicines so they are not prescribed to men who only have problems related to aging, such as low energy and libido. The paper notes use of testosterone quadrupled since early 2000s for men in their 40s, amid a marketing push.
להמשך קריאה

FDA Advisory Panel Backs Approval Of Obesity Treatment.
An outside FDA advisory panel recommended approval of anti-obesity drug Saxenda (liraglutide), which at lower doses is marketed as Victoza for diabetes. A clinical study found 60 percent of patients on Saxenda for a year lost at least 5 percent weight, and 31 percent lost more than 10 percent. In contrast, among patients taking a sham treatment only 24 percent lost 5 percent of weight and 9 percent more than 10 percent.
להמשך קריאה

FDA Approves New Obesity Medication.
FDA’s approved Orexigen Therapeutics’ anti-obesity medicine Contrave (bupropion and naltrexone), the third new prescription drug for obesity since 2012. The two other drugs  are Qsymia (phentermine and topiramate) fromVivus, and Belviq (lorcaserin HCl) from Arena Pharmaceuticals and Eisai. In a clinical trial significant weight loss was achieved by 42% of people on Contrave vs 17% of people on placebo. Another study in type 2 diabetes patients found significant weight loss of 36% for Contrave vs 18% for placebo.
להמשך קריאה

Franz Joseph Kallmann was born in 1897 in Neumarkt, Silesia Germany, the son of Marie and Bruno Kallmann. Bruno was a surgeon who had converted from Judaism to Christianity. Franz Joseph received the MD degree from the University of Breslau in 1919 and further training in psychiatry under Karl Bonhoffer and Creutzfeld in Berlin. Early in his carrier he became interested on the role of genetic factors in schizophrenia, and between 1929 and 1935 was granted several fellowships at the Psychiatric Research Institute in Munich, later the Max-Planck Institute, in the department headed by the Swiss psychiatrist Ernst Rudin. On July 14, 1933, the Nazi government issued its "Law for the Prevention of Progeny with Hereditary Diseases". Rudin coauthored the memorandum and implementation guidelines for the law. In 1935, Kallmann presented an article at the International Congress for Population Science in Berlin hosted by Hitler Interior Ministry. In his speech he advocated the examination of all relatives of individuals with schizophrenia to identify non-affected carriers, which he believed could be done by noting ‘‘minor anomalies” and then the compulsory sterilization of such individuals. The next year he immigrated to America because he was half-Jewish and soon established the Medical Genetics Department of the New York State Psychiatric Institute affiliated to Columbia University. Kallmann’s first major work, published simultaneously in USA and Germany in 1938,  was a family study of schizophrenia in 13,851 relatives of 1,087 patients admitted to a Berlin hospital in a ten year period. In this study he reported an 11-16% prevalence rate of schizophrenia among relatives compared to less than 1% in the general population, implying the hereditary nature of the disease. The next year the German Nazi government began the Action T4 program targeting defective persons as defined by law, ending in the sterilization and killing of some 250,000 schizophrenics among others.  Although Kallman has been considered a Nazi victim by some, he was criticized by others because of his eugenic views and for helping Rudin in the denazification proceedings. He was also dedicated to demonstrate a genetic basis for homosexuality. In 1952, he wrote “Taking notice of this generally unsatisfactory state of information about the genetic aspects of adult homosexual behavior… our investigative program was planned as a concentric and strategically coordinated attack from different directions” and concluded “In any case; the need of additional work in relation to the genetic aspects of homosexuality cannot possibly be questioned. The urgency of such work is undeniable as long as this aberrant type of behavior continues to be an inexhaustible source of unhappiness, discontentment, and a distorted sense of human values.” In the following years Kallmann established himself in the forefront of genetic psychiatry. He became well known in the fields of endocrinology for his description in 1944 of three different families in which a majority of the members had a syndrome consisting of missing puberty, anosmia, and colour blindness, drawing drew attention to the genetic aetiology of the disorder. In 1948 he became one of the founders of the American Society of Human Genetics. In 1954 was appointed full professor at Columbia University. During 1952-1965 he was member of the Board of Directors of the American Eugenics Society. Franz Kallmann died in 1965 at the age of 68 in New York

References:
Cohen M, Am J Med Genet 2010, 152a:687
Gershon E, Arch Psychiatr Neurol Sci 1981, 229:273
Gottesman I et al. Am J Med Genet 1996, 67:317

להתראות בגיליון הבא !

עורך: דר' קרלוס בן בסט
carlosb@netvision.net.il